Zobrazeno 1 - 10
of 10
pro vyhledávání: ''
Autor:
Chun Gong, Fei-jiao Ge, Ming Ni, Jianming Xu, Rongrui Liu, Chuanhua Zhao, Jun-Yan Gu, Yan Wang, Zhaoli Tan, Ru Jia, Mansheng Li, Shuji Ogino, He-Fei Wang, Yang Jin, Yunping Zhu, Li Lin, Youliang Wang, Yu Ling Chen, Tao Liu, Zhi Rong Qian
Publikováno v:
Clinical Cancer Research. 23:4602-4616
Purpose: Mutations in KRAS are considered to be the main drivers of acquired resistance to epidermal growth factor receptor (EGFR) blockade in patients with metastatic colorectal cancer (mCRC). However, the potential role of other genes downstream of
Autor:
Si-Yang Liu, Qing Zhou, Lan-Ying Gou, A. Li, Zhi-Hong Chen, Bin Gan, Hua-Jun Chen, Bin-Chao Wang, Jian Su, Chong-Rui Xu, Qi Zhang, Jin-Ji Yang, Zheng Wang, Xue-Ning Yang, Zhenfan Yang, Shannon Chuai, Han Han-Zhang, Zhen Wang, Zhi Xie, Wen-Zhao Zhong, Zhou Zhang, Yu Bai, Xu-Chao Zhang, Si-Pei Wu, Ben-Yuan Jiang, Hong-Fei Gao, Yi-Long Wu
Publikováno v:
Clinical Cancer Research. 23:4929-4937
Purpose: MET amplification, responsible for 20% of acquired resistance to EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non–small cell lung cancer (NSCLC), presents an attractive target. Numerous studies have conferred susceptibili
Autor:
Jonathan H. Sheehan, Carlos L. Arteaga, Michael F. Berger, James P. Koch, Richard E. Cutler, Vincent A. Miller, Ariella B. Hanker, Rebecca J. Nagy, Gregory Sliwoski, David M. Hyman, Christine M. Lovly, Jie He, Alshad S. Lalani, Jens Meiler, Monica Red Brewer, David B. Solit, Richard B. Lanman, Darren Cross
Publikováno v:
Cancer Discovery. 7:575-585
We report a HER2T798I gatekeeper mutation in a patient with HER2L869R-mutant breast cancer with acquired resistance to neratinib. Laboratory studies suggested that HER2L869R is a neratinib-sensitive, gain-of-function mutation that upon dimerization w
Autor:
Wen Jia Zuo, Zhi Ming Shao, Jiong Wu, Guang Yu Liu, Yi-Zhou Jiang, Gen Hong Di, Xin Hu, Y. Wang, Ke Da Yu, Xiao En Xu
Publikováno v:
Clinical Cancer Research. 22:4859-4869
Purpose: Somatic mutations in the tyrosine kinase domain of human epidermal growth factor receptor 2 (HER2) may be an alternative mechanism to HER2 activation and can affect the sensitivity toward HER2-targeted therapies. We aimed to investigate the
Autor:
Lukas C. Heukamp, William Pao, Helen Pasternack, Christian Becker, Kerstin Albus, Matthias Scheffler, Reinhard Buettner, Johannes M. Heuckmann, Alexandra Florin, Martin L. Sos, Andreas H. Scheel, Jana Fassunke, Martin Peifer, Thorsten Persigehl, Sabine Merkelbach-Bruse, Sebastian Michels, Marc Bos, Lynnette Fernandez-Cuesta, Janine Altmüller, Dennis Plenker, Jürgen Wolf, Lydia Meder, Sandra Ortiz-Cuaran, Johannes Berg, llona Dahmen, Michaela Angelika Ihle, Carina Heydt, Hongbin Ji, Rieke Fischer, Roman K. Thomas, Christian Müller, Peter Nuernberg, Sascha Ansén, Christine M. Lovly, Hans-Ulrich Schildhaus, Katharina König
Publikováno v:
Clinical Cancer Research. 22:4837-4847
Purpose: To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or rociletinib (CO-1686). Experimental Design: We analyzed tumor biopsies f
Autor:
Takatsugu Okegawa, Shuta Tomida, Suguru Hamada, Kikuo Nutahara, Hidetoshi Hayashi, Kazuko Sakai, Masato Terashima, Kazuto Nishio, Yu Nakamura, Yosuke Togashi, Yoshihiko Fujita, Eri Banno, Marco A. De Velasco, Hirokazu Nakahara
Publikováno v:
Molecular Cancer Therapeutics. 15:1988-1997
The prognosis for patients with advanced esophageal or head-and-neck squamous cell carcinoma (ESCC or HNSCC) remains poor, and the identification of additional oncogenes and their inhibitors is needed. In this study, we evaluated the sensitivities of
Autor:
Dan L. Sackett, Alex Kagansky, Susan E. Bates, Jung-Hyun Kim, Jane B. Trepel, Nicholas C.O. Lee, Hee-Sheung Lee, Yves Pommier, Natalay Kouprina, Vladimir Larionov
Publikováno v:
Cancer Research. 76:902-911
Whole chromosomal instability (CIN), manifested as unequal chromosome distribution during cell division, is a distinguishing feature of most cancer types. CIN is generally considered to drive tumorigenesis, but a threshold level exists whereby furthe
Autor:
Russo, Mariangela, Siravegna, Giulia, Blaszkowsky, Lawrence S., Corti, Giorgio, Crisafulli, Giovanni, Ahronian, Leanne G., Mussolin, Benedetta, Kwak, Eunice L., Buscarino, Michela, Lazzari, Luca, Valtorta, Emanuele, Truini, Mauro, Jessop, Nicholas A., Robinson, Hayley E., Hong, Theodore S., Mino Kenudson, Mari, DI NICOLANTONIO, Federica, Thabet, Ashraf, Sartore Bianchi, Andrea, Siena, Salvatore, Iafrate, John, Bardelli, Alberto, Corcoran, Ryan B., joint co last authorshipjoint corresponding authorship
Publikováno v:
Cancer Discovery. 6:147-153
How genomic heterogeneity associated with acquired resistance to targeted agents affects response to subsequent therapy is unknown. We studied EGFR blockade in colorectal cancer to assess whether tissue and liquid biopsies can be integrated with radi
Autor:
Nadia Russolillo, Salvatore Siena, Enzo Medico, Michela Buscarino, Federica Di Nicolantonio, Davide Torti, Paolo Massucco, Alberto Bardelli, Alberto Pisacane, Luca Molinaro, Francesco Galimi, Andrea Bertotti, Mauro Risio, Davide Corà, Emanuele Valtorta, Giorgia Migliardi, Francesco Sassi, Claudio Isella, Lorenzo Capussotti, Paolo M. Comoglio, Andrea Muratore, Anna Sapino, Consalvo Petti, Livio Trusolino, Silvia Marsoni, Andrea Sartore-Bianchi, Marcello Gambacorta, Dario Ribero
Publikováno v:
Cancer Discovery; Vol 1
Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the identification of novel biomarkers for better personalized medicine.
Autor:
L-A Martin, I.E. Smith, Mitchell Dowsett, Pascal Gellert, Isaac Garcia-Murillas, Belinda Yeo, Nicholas C. Turner, Sunil Pancholi, Ricardo Ribas, Andrew D.J. Pearson, Elena Lopez-Knowles
Publikováno v:
Cancer Research. 76:S6-02
Background: There is great interest in the mutational landscape of metastatic breast cancer (BC) for personalised medicine. Knowledge about how this landscape differs in recurrent lesions from primary BC as a result of metastatic selection or the imp